These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25866151)

  • 1. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
    Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
    Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant astrocytes impair vascular reactivity in Huntington disease.
    Hsiao HY; Chen YC; Huang CH; Chen CC; Hsu YH; Chen HM; Chiu FL; Kuo HC; Chang C; Chern Y
    Ann Neurol; 2015 Aug; 78(2):178-92. PubMed ID: 25914140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurovascular abnormalities in humans and mice with Huntington's disease.
    Lin CY; Hsu YH; Lin MH; Yang TH; Chen HM; Chen YC; Hsiao HY; Chen CC; Chern Y; Chang C
    Exp Neurol; 2013 Dec; 250():20-30. PubMed ID: 24036415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupted vasculature and blood-brain barrier in Huntington disease.
    Waldvogel HJ; Dragunow M; Faull RL
    Ann Neurol; 2015 Aug; 78(2):158-9. PubMed ID: 26018216
    [No Abstract]   [Full Text] [Related]  

  • 6. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
    Ransome MI; Hannan AJ
    Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
    Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
    Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.
    Björkqvist M; Petersén A; Bacos K; Isaacs J; Norlén P; Gil J; Popovic N; Sundler F; Bates GP; Tabrizi SJ; Brundin P; Mulder H
    Hum Mol Genet; 2006 May; 15(10):1713-21. PubMed ID: 16613897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.
    Lewandowski NM; Bordelon Y; Brickman AM; Angulo S; Khan U; Muraskin J; Griffith EY; Wasserman P; Menalled L; Vonsattel JP; Marder K; Small SA; Moreno H
    Neurobiol Dis; 2013 Apr; 52():84-93. PubMed ID: 23220414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
    Smith R; Petersén A; Bates GP; Brundin P; Li JY
    Neurobiol Dis; 2005 Dec; 20(3):673-84. PubMed ID: 15967669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
    Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
    Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.